PARP1 and cancer: PARP inhibitors exhibit anti-tumor activity by a process known as “synthetic lethality”—the idea that cancer cell inactivation of two genetic pathways leads to cell death while disruption of one pathway alone is non-lethal (Figure 3) [16,23].